制定处方点评标准在促进骨科中成药临床合理应用中的价值研究

Study on the Value of Prescription Review Criteria Establishment in Promoting Clinical Rational Use of Chinese Patent Medicines in Orthopedics Department

目的:探讨制定骨科中成药处方点评标准在促进该类药物临床合理应用中的价值。方法:基于骨科相关指南、专家共识推荐,结合临床处方制定骨科中成药处方点评标准,对参与点评的临床药师进行一系列相关知识培训。选取标准推行前后的3个月(即2022年10~12月和2023年5~7月)内骨科中成药处方各3000张,参照标准进行系统点评分析。结果:2022年10~12月骨科中成药处方合理率为96.13%;在2023年5~7月的复查中,该类处方合理率提高至98.10%,不合理处方数量明显下降。结论:制定处方点评标准有效促进了骨科中成药的临床合理应用,可大幅度提高医生用药准确性,保障患者用药安全。

Objective:To explore the value of establishing the prescription review criteria for Chinese patent medicines in Orthopedics Department in promoting the clinical rational use of such drugs.Methods:Based on orthopedic guidelines,expert consensus recommendation and clinical prescriptions,the prescription review criteria for Chinese patent medicines in Orthopedics Department were established,and the clinical pharmacists involved in the review were trained on a series of relevant knowledge.In the three months(i.e.from October to December 2022 and from May to July 2023)before and after the implementation of the criteria,3000 prescriptions of Chinese patent medicines in Orthopedics Department each were selected for systematic review and analysis with reference to the criteria.Results:The rational rate for prescription of Chinese patent medicines in Orthopedics Department from October to December 2022 was 96.13%.In the subsequent review from May to July 2023,the rational rate for prescription of such drugs increased to 98.10%,and the number of irrational prescriptions decreased significantly.Conclusion:The established prescription review criteria effectively promoted the clinical rational use of Chinese patent medicines in Orthopedics Department and greatly improved the physician's prescription accuracy,thereby ensuring the medication safety in patients.